Objective: MicroRNAs (miRNAs) are small noncoding RNAs that regulate gene expression and serve as promising therapeutic targets in many diseases. MiRNAs are also present in biological fluids and may be of use as disease biomarkers. We evaluated whether miRNAs are differentially regulated in the CSF of patients with multiple sclerosis (MS).
Results:
After global miRNA profiling, we quantitatively confirmed miR-922 (p 5 0.0001), miR181c (p 5 0.0007), and miR-633 (p 5 0.0014) to be differentially regulated in patients with MS as compared with OND. Importantly, miR-181c and miR-633 differentiated relapsing-remitting from secondary progressive MS courses with specificity up to of 82% and a sensitivity of 69%.
Conclusion: CSF-based miRNAs were differentially regulated in patients with MS as compared with OND and in different MS disease courses. Despite the preliminary character of our case-control study, the results provide rationale for a confirmation study in larger MS cohorts. Neurology MicroRNAs (miRNAs) "fine-tune" gene expression on the posttranscriptional level by binding to target mRNAs, which leads to either degradation or translational repression. 1 miRNAs control development and tissue homeostasis and are critically involved in many biological processes in health and disease including neurologic diseases such as multiple sclerosis (MS). 2 The potential therapeutic value of miRNAs has also been appreciated in experimental disease setups. [3] [4] [5] The putative role of miRNAs in MS emerges from miRNA profiling analyses in active MS lesions. 6 In this study, upregulation of 3 distinct miRNAs-miR-34a, miR-155, and miR-326-was shown to promote macrophage activity. 6 Findings from an animal model of MS also support the involvement of miRNAs, in particular miR-124, 3 in the pathophysiology of MS. Human MS studies showed altered miRNA expression patterns in whole blood samples, peripheral blood monocytes, and lymphocyte subpopulations from patients with MS. 2 However, the results of these studies are widespread and in some cases reveal conflicting conclusions. For instance, miR-17 and miR-20a, which belong to the miR-17-92 cluster, were significantly downregulated in all MS subtypes, 7 whereas miRNAs of the same cluster were upregulated in another study. 8 Apart from possible methodologic artifacts, the diverse findings may result from varying disease subcohorts that did not consider different MS courses. Given these potential sources of biases inflicted by a compartment such as peripheral blood, analysis of miRNA patterns in a confined compartment such as the CSF, which reflects the local milieu of the CNS best, may provide a more robust indicator of MS-related disease activity.
We recently demonstrated high stability of miRNAs in a study analyzing miRNAs in CSF of patients with CNS lymphoma: neither exposure to RNase, nor repeated freeze-thaw cycles and long-term storage of CSF samples, affected miRNA levels in the CSF. 9 In this study, we profiled miRNAs in the CSF of patients with MS and patients with other neurologic diseases (OND). Our analysis unveiled regulated miRNAs in the CSF of patients with MS discriminating 1) disease courses of MS and 2) MS from OND.
METHODS Standard protocol approvals, registrations, and patient consents. In accordance with the Ruhr-University Bochum ethics committee standard on CSF sample collection, since February 2009, the remaining CSF of samples obtained for routine diagnostic and therapeutic purposes after written informed consent, including patients with MS and OND, was collected and stored at 280°C. For this study, we assessed the CSF of n 5 53 patients with MS who had clinically well-defined disease courses and n 5 39 patients with OND. Details of patients' characteristics are summarized in table 1.
RNA isolation and global miRNome analysis. Before freezing, all cells and debris in CSF samples were removed by centrifugation in a routine manner and cell numbers recorded for diagnostic purposes; hemorrhagic samples were excluded. After adding spiked-in control Caenorhabditis elegans miR-39 as an internal control, total RNA was isolated from 200 mL CSF using the miRNeasy Mini Kit (Qiagen, Hilden, Germany), according to the manufacturer's instructions. An miRNA transcriptome analysis including 760 miRNAs in pooled CSF from n 5 10 patients with MS and n 5 10 patients with OND was performed by using an miRNome micro-RNA Profilers QuantiMir Human PCR array on 2 plates each with 380 miRNAs (cat. no.: RA660A-1, version 15; BioCat, Heidelberg, Germany) according to the manufacturer's instructions and using a robotic-assisted automatic pipetting device (Agilent, Santa Clara, CA).
A (SPMS, n 5 30) showed significantly downregulated levels of miR-633 (p 5 0.0005) and miR-181c (p 5 0.02) in SPMS as compared with RRMS ( figure  1) . Because of the small sample size of patients with primary progressive MS (n 5 6), this cohort was not included in further analyses.
Differentiating value of candidate miRNAs. To evaluate the differentiating value of the candidate miRNAs, we determined miRNA specific cutoff levels deduced from receiver operating characteristic curves, as depicted in figure e-1 (area under the curve [AUC] of 0.73 for miR-NA-181c, AUC of 0.82 for miR-633, AUC of 0.74 for miR-922). Combining candidate miRNAs in an analysis tree, as shown in figure 2 , resulted in enhanced specificity and sensitivity values. The combination of a cutoff value ,0.35 for miR-633 (RR, 1.9; 95% CI, 1.2-2.9; p 5 0.0065) and .0.47 for miR-181c (RR, 2.0; 95% CI, 1.1-3.7; p 5 0.011) led to 69% sensitivity and 82% specificity for the discrimination between RRMS and SPMS ( figure 2A) . Accordingly, the combination of a cutoff value .0.73 for miR-633 (RR, 6.1; 95% CI 2.0-18.2; p , 0.0001) and ,0.04 for miR-922 (RR, 2.2; 95% CI, 1.4-3.4; p , 0.0001) led to 88% sensitivity and 69% specificity for the differentiation between MS and OND ( figure 2B ).
DISCUSSION In this study, we indentified 3 regulated miRNAs in the CSF of patients with MS, namely, miR181c, miR-633, and miR-922 (figure 1). Patients with MS included in our study had been well characterized regarding course of disease, allowing a CSF miRNAbased differentiation according to MS disease course; miR-181c and miR-633 were differentially regulated in RRMS and SPMS. Moreover, the combination of both led to feasible specificity and sensitivity levels ( figure 2A ). In addition, MS CSF revealed deregulated levels of all 3 miRNAs compared with OND ( figure 1) . Notably, besides neurodegenerative diseases, our OND cohort also included patients with various neuroinflammatory disorders, such as neuromyelitis optica, that are among differential diagnoses of MS (table 1) , which supports the potential diagnostic value of these CSFbased miRNAs (figure 2B). Growing evidence from large histopathologic studies has unveiled different patterns of early active inflammatory lesions in MS brains pointing to heterogeneous pathomechanisms that are comprised by MS as a single disease. 10 These observations are supported by the clinical heterogeneity and the different MRI characteristics of the lesions and even the response to therapy. Moreover, despite ample research effort, the reason for conversion of RRMS to SPMS remains enigmatic and markers indicating the turning point in disease course are missing. miR-181c and miR-633 in the CSF may offer additional information about the mechanism of brain lesion activity beyond their differentiating potential.
Reports from various disciplines, e.g., oncology, cardiovascular research, and infectiology, have demonstrated the potential diagnostic and prognostic value of miRNAs in circulating blood and CSF, as well as their therapeutic capability in the clinical arena. 1 The functional role of disease-associated miRNAs, which are remarkably stable in body fluids, remains to be solved-whether they are causative or reflect a response to a pathologic situation as distant messengers.
1 At this stage, we can only speculate on source and function of the regulated CSF miRNAs in MS. Although it is widely assumed that miRNAs do not cross the blood-brain barrier, there is evidence from the field of oncology that malignant cells act as transporters of miRNAs from the blood to the CNS compartment to promote local tumor growth. 11, 12 Also speaking in favor of the peripheral blood compartment as a possible miR-NA source in the CSF is the well-known and pathophysiologically relevant breakdown of the blood-brain barrier during active inflammation in MS. Conversely, an argument rather supporting the CNS as origin of the regulated miRNAs is that these miRNAs have not been identified in studies analyzing the peripheral blood compartment and peripheral immune cells of patients with MS. 2, [6] [7] [8] Whether these miRNAs are set free by active or apoptotic immune effector cells involved in demyelination or a response of the attacked glial/neuronal cells remains to be determined.
However relevant to the MS field, at this stage, our data do not allow the conclusion that the candidate miRNAs shown here are ready to be used as diagnostic markers. The limitations of our data are 1) the relatively small sample size; 2) a cohort from a confined geographic area with less heterogenous background; and 3) thus far, primary progressive MS, neuromyelitis optica, and clinically isolated syndrome are not addressed. Nevertheless, the results of our study contribute to the new avenue of miRNA biology in MS and provide the rationale for larger MS cohort studies that are certainly needed to further confirm our preliminary results of regulated CSFbased miRNAs. 
